Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS-553 in Relapsed or Refractory CLL/SLL
NCT05272813Phase 2Terminated
- Sponsor
- MingSight Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of MS-553 in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (4 arms), sponsored by MingSight Pharmaceuticals. Primary endpoint: Incidence of Dose Limiting Toxicities at 28 days. Started Apr 2022; status: terminated.
02
Drugs
MS-553
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05272813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05272813.